World-class liquid biopsy testing will be
available to SOPHiA GENETICS customers
BOSTON and ROLLE, Switzerland, Dec. 7, 2023
/PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native
software company and a leader in data-driven medicine, today
announced an expanded suite of solutions under SOPHiA DDM™ for
Liquid Biopsy. The range of solutions, including MSK-ACCESS®
powered with SOPHiA DDM™ and custom solutions, will help progress
oncology research and tumor mutation profiling. The rollout of
SOPHiA GENETICS' liquid biopsy capabilities demonstrates the
company's commitment to developing advanced solutions that empower
timely, critical decision-making and improve health outcomes.
For a sizeable number of cases, genomic testing of tumor tissue
is not feasible due to either insufficient tissue material, low
quality of the obtained tissue, or the invasiveness of the
procedure. Liquid biopsy testing offers an alternative to solid
tumor testing by isolating cell-free DNA (cfDNA) from blood plasma,
which may uncover circulating tumor DNA (ctDNA). Isolating these
DNA samples from a simple blood draw can help guide clinical
decisions in a manner that is faster and less invasive,
expedite results for researchers and clinicians, and simplify
monitoring. SOPHiA GENETICS' liquid biopsy offering will help users
enhance tumor profiling with advanced cfDNA analysis and a
streamlined DNA-only NGS workflow, allowing users to go from
extracted cfDNA to comprehensive report in an efficient timeframe.
SOPHiA DDM™ for Liquid Biopsy features SOPHiA GENETICS'
proprietary unique molecular identifier technology (CUMIN™) that is
designed to transform the way labs analyze cell-free DNA samples
with exceptional performance and reliable results.
"Our goal at SOPHiA GENETICS is to increase the use of
data-driven medicine around the world and decrease health
inequities by making resources more accessible to all," said
Philippe Menu, MD, PhD., Chief Medical Officer and Chief Product
Officer, SOPHiA GENETICS. "Liquid
biopsy is a sophisticated testing capability that can help expedite
clinical decisions and planning. It is inherently cheaper and
faster than traditional biopsy methods and is an excellent tool for
labs and health systems to have at their disposal. We feel strongly
that increased use of liquid biopsy will help advance oncology care
and we are excited to help our customers implement this
offering."
Customers interested in implementing a liquid biopsy offering
via SOPHiA DDM™ have different options based on their individual
needs. MSK-ACCESS® powered with SOPHiA DDM™ is a
decentralized version of a highly validated ctDNA assay
developed by Memorial Sloan Kettering (MSK) that involves the deep
sequencing of 146 key cancer-associated genes. Customers utilizing
the SOPHiA DDM™ Platform for solid tumor applications can adapt
their panels to include liquid biopsy samples; and for customers
who have unique challenges or who focus on specific biomarkers,
SOPHiA GENETICS offers custom liquid biopsy applications built in
partnership with the SOPHiA GENETICS team.
The SOPHiA GENETICS liquid biopsy solutions incorporate the
company's state-of-the-art proprietary algorithms and advanced
genomic analysis, made possible with artificial intelligence (AI),
to provide customers with expedited and streamlined insights that
increase the ability of clinician researchers to practice precision
medicine. Additionally, the SOPHiA GENETICS solutions allow
customers to retain full ownership of their databases and obtain
reproducible data that can help accelerate future work.
The SOPHiA GENETICS liquid biopsy solutions are now available
for customers worldwide. Learn more about clinical applications for
liquid biopsy testing here, and for more information on SOPHiA DDM™
for Liquid Biopsy, visit SOPHiAGENETICS.com or connect
on X, LinkedIn, Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on X, LinkedIn, Facebook,
and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures, unless specified otherwise.
MSK-ACCESS® powered with SOPHiA DDM™ is a product in development
and may not be available for sale. The information in this
press release is about products that may or may not be available in
different countries and, if applicable, may or may not have
received approval or market clearance by a governmental regulatory
body for different indications for use. Please contact
support@sophiagenetics.com to obtain the appropriate product
information for your country of residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains statements
that constitute forward-looking statements. All statements other
than statements of historical facts contained in this press
release, including statements regarding our future results of
operations and financial position, business strategy, products, and
technology, as well as plans and objectives of management for
future operations, are forward-looking statements. Forward-looking
statements are based on our management's beliefs and assumptions
and on information currently available to our management. Such
statements are subject to risks and uncertainties, and actual
results may differ materially from those expressed or implied in
the forward-looking statements due to various factors, including
those described in our filings with the U.S. Securities and
Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-announces-expanded-suite-of-liquid-biopsy-offerings-302008629.html
SOURCE SOPHiA GENETICS